Tamoxifen Citrate

• Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cance… Pending
  2024-517315-69-00 Phase III 1 country Uppsala University
• Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE) Recruiting
  2024-516282-37-00 Phase II 1 country Institut De Cancerologie De L Ouest
• Randomized double blind phase 2 trial of baby exemestane versus baby tamoxifen in postmenopausal women at high risk for breast cancer Recruiting
  2024-520004-26-00 Phase II 2 countries Ente Ospedaliero Ospedali Galliera Di Genova
• A clinical study of MK-5684 in people with certain solid tumors (MK-5684-015) Recruiting
  2024-519563-18-00 Phase II/III 1 country Merck Sharp & Dohme LLC
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 Phase III 16 countries AstraZeneca AB
• Phase II, multicenter, randomized, open-label study of premenopausal women with luminal breast cancer investigating the effect of elacestran… Recruiting
  2023-503373-37-01 Phase II 1 country Solti Group
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 Phase II 1 country The Royal Marsden NHS Foundation Trust
• Breast cancer prevention in women at increased risk using low dose tamoxifen and/or diet and life style changes: a randomized 4 arms clinica… Ended
  2023-503994-39-00 Phase II 1 country Istituto Europeo Di Oncologia S.r.l.
• A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended
  2023-506821-12-00 Phase III 4 countries Genentech Inc.
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended
  2022-501024-20-00 Phase III 14 countries Astrazeneca AB
• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended
  2023-509923-42-00 Phase II 5 countries Medica Scientia Innovation Research S.L.
• A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer Ended
  2023-507175-22-00 Phase II 1 country Eli Lilly & Co.

Showing 1–12 of 12 trials